Abstract
Endocannabinoids (ECS) constitute lipid mediators (amides, esters, and ethers of long chain polyunsaturated fatty acids) which act similarly to the exogenous Δ9 tetrahydrocannabinol (THC; the main psychoactive ingredient of the plant Cannabis sativa) and are produced in humans and animals (Maccarrone et al. 2003; Rahn and Hohmann 2009). The cutaneous ECS system is fully functional due to the expression of ECS and their receptors as well as ECS-degrading enzymes. All the components of the skin ECS system were shown to modulate the proliferation, differentiation, growth, and apoptosis of various skin cell types as well as tumorigenesis and local cytokine production (reviewed by Biro et al. 2009; Kupczyk et al. 2009; Toth et al. 2011). ECS are synthesized “on demand” by receptor-stimulated cleavage of membrane lipid precursors and are not stored in synaptic vesicles which distinguishes them from typical neurotransmitters. ECS reuptake may be facilitated by a transporter that has not been cloned yet; however, pharmacological inhibitors of ECS transport have nonetheless been developed (Guindon and Hohmann 2009). The lipophilic nature of ECS allows them to activate various enzymes in cytosol and membraneous compartments (Kupczyk et al. 2009).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abrams DI, Couey P, Shade SB, Kelly ME, Benowitz NL (2011) Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther 90:844–851
Akerman S, Kaube H, Goadsby PJ (2004) Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors. Br J Pharmacol 142:1354–1360
Akhmetshina A, Dees C, Busch N, Beer J, Sarter K, Zwerina J, Zimmer A, Distler O, Schett G, Distler JH (2009) The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis Rheum 60:1129–1136
Amaya F, Shimosato G, Kawasaki Y, Hashimoto S, Tanaka Y, Ji RR, Tanaka M (2006) Induction of CB1 cannabinoid receptor by inflammation in primary afferent neurons facilitates antihyperalgesic effect of peripheral CB1 agonist. Pain 124(1–2):175–183
Biro T, Toth BI, Hasko G, Paus R, Pacher P (2009) The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends Pharmacol Sci 30:411–420
Blazquez C, Carracedo A, Barrado L, Real PJ, Fernandez-Luna JL, Velasco G, Malumbres M, Guzman M (2006) Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J 20:2633–2635
Casanova ML, Blazquez C, Martinez-Palacio J, Villanueva C, Fernandez-Acenero MJ, Huffman JW, Jorcano JL, Guzman M (2003) Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 111:43–50
Connell K, Bolton N, Olsen D, Piomelli D, Hohmann AG (2006) Role of the basolateral nucleus of the amygdala in endocannabinoid-mediated stress-induced analgesia. Neurosci Lett 397:180–184
Dvorak M, Watkinson A, Mcglone F, Rukwied R (2003) Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin. Inflamm Res 52:238–245
Finn DP (2010) Endocannabinoid-mediated modulation of stress responses: physiological and pathophysiological significance. Immunobiol 215:629–646
Guindon J, Hohmann AG (2009) The endocannabinoid system and pain. CNS Neurol Disord Drug Targets 8:403–421
Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A, Davar G, Makriyannis A, Vanderah TW, Mata HP, Malan TP Jr (2005) CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci USA 102:3093–3098
Irving AJ, Rae MG, Coutts AA (2002) Cannabinoids in the brain. Scientific World J 2:632–648
Karsak M, Gaffal E, Date R, Wang-Eckhardt L, Rehnelt J, Petrosino S, Starowicz K, Steuder R, Schlicker E, Cravatt B, Mechoulam R, Buettner R, Werner S, Di Marzo V, Tuting T, Zimmer A (2007) Attenuation of allergic contact dermatitis through the endocannabinoid system. Science 316:1494–1497
Karst M, Wippermann S, Ahrens J (2010) Role of cannabinoids in the treatment of pain and (painful) spasticity. Drugs 70:2409–2438
Kircik L (2010) A nonsteroidal lamellar matrix cream containing palmitoylethanolamide for the treatment of atopic dermatitis. J Drugs Dermatol 9:334–338
Kupczyk P, Reich A, Szepietowski JC (2009) Cannabinoid system in the skin—a possible target for future therapies in dermatology. Exp Dermatol 18:669–679
Maccarrone M, Di Rienzo M, Battista N, Gasperi V, Guerrieri P, Rossi A, Finazzi-Agro A (2003) The endocannabinoid system in human keratinocytes. Evidence that anandamide inhibits epidermal differentiation through CB1 receptor-dependent inhibition of protein kinase C, activation protein-1, and transglutaminase. J Biol Chem 278:33896–33903
Oka S, Wakui J, Ikeda S, Yanagimoto S, Kishimoto S, Gokoh M, Nasui M, Sugiura T (2006) Involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in oxazolone-induced contact dermatitis in mice. J Immunol 177:8796–8805
Pacher P, Mechoulam R (2011) Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res 50:193–211
Paradisi A, Pasquariello N, Barcaroli D, Maccarrone M (2008) Anandamide regulates keratinocyte differentiation by inducing DNA methylation in a CB1 receptor-dependent manner. J Biol Chem 283:6005–6012
Pucci M, Pirazzi V, Pasquariello N, Maccarrone M (2011) Endocannabinoid signaling and epidermal differentiation. Eur J Dermatol Suppl 2:29–34
Rahn EJ, Hohmann AG (2009) Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics 6:713–737
Roosterman D, Goerge T, Schneider SW, Bunnett NW, Steinhoff M (2006) Neuronal control of skin function: the skin as a neuroimmunoendocrine organ. Physiol Rev 86:1309–1379
Sagar DR, Staniaszek LE, Okine BN, Woodhams S, Norris LM, Pearson RG, Garle MJ, Alexander SP, Bennett AJ, Barrett DA, Kendall DA, Scammell BE, Chapman V (2010) Tonic modulation of spinal hyperexcitability by the endocannabinoid receptor system in a rat model of osteoarthritis pain. Arthritis Rheum 62:3666–3676
Sanchez AJ, Garcia-Merino A (2012) Neuroprotective agents: Cannabinoids. Clin Immunol 142:57–67
Slominski A, Wortsman J (2000) Neuroendocrinology of the skin. Endocrine Rev 21:457–487
Srivastava BK, Soni R, Patel JZ, Joharapurkar A, Sadhwani N, Kshirsagar S, Mishra B, Takale V, Gupta S, Pandya P, Kapadnis P, Solanki M, Patel H, Mitra P, Jain MR, Patel PR (2009) Hair growth stimulator property of thienyl substituted pyrazole carboxamide derivatives as a CB1 receptor antagonist with in vivo antiobesity effect. Bioorg Med Chem Lett 19:2546–2550
Stander S, Schmelz M, Metze D, Luger T, Rukwied R (2005) Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci 38:177–188
Steinhoff M, Bienenstock J, Schmelz M, Maurer M, Wei E, Biro T (2006) Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus. J Invest Dermatol 126:1705–1718
Su TF, Zhang LH, Peng M, Wu CH, Pan W, Tian B, Shi J, Pan HL, Li M (2011) Cannabinoid CB2 receptors contribute to upregulation of beta-endorphin in inflamed skin tissues by electroacupuncture. Mol Pain 7:98, (Epub ahead of print) PMID: 22177137
Telek A, Biro T, Bodo E, Toth BI, Borbiro I, Kunos G, Paus R (2007) Inhibition of human hair follicle growth by endo- and exocannabinoids. FASEB J 21:3534–3541
Toth BI, Dobrosi N, Dajnoki A, Czifra G, Olah A, Szollosi AG, Juhasz I, Sugawara K, Paus R, Biro T (2011) Endocannabinoids modulate human epidermal keratinocyte proliferation and survival via the sequential engagement of cannabinoid receptor-1 and transient receptor potential vanilloid-1. J Invest Dermatol 131:1095–1104
Yosipovitch G (2010) Chronic pruritus: a paraneoplastic sign. Dermatol Ther 23:590–596
Zhao ZG, Li YY, Yang J, Li HJ, Zhao H (2010) Expression of cannabinoid receptor 2 in squamous cell carcinoma. Nan Fang Yi Ke Da Xue Xue Bao 30:593–595
Zheng D, Bode AM, Zhao Q, Cho YY, Zhu F, Ma WY, Dong Z (2008) The cannabinoid receptors are required for ultraviolet-induced inflammation and skin cancer development. Cancer Res 68:3992–3998
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2012 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Slominski, A.T., Zmijewski, M.A., Skobowiat, C., Zbytek, B., Slominski, R.M., Steketee, J.D. (2012). Cutaneous Endocannabinoid System. In: Sensing the Environment: Regulation of Local and Global Homeostasis by the Skin's Neuroendocrine System. Advances in Anatomy, Embryology and Cell Biology, vol 212. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-19683-6_11
Download citation
DOI: https://doi.org/10.1007/978-3-642-19683-6_11
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-19682-9
Online ISBN: 978-3-642-19683-6
eBook Packages: MedicineMedicine (R0)